




DFW

PATENT--NO FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	)	I hereby certify that this
	)	paper is being deposited
ANIL GULATI	)	with the United States
	)	Postal Service with suffi-
Serial No.: 10/691,915	)	cient postage, as first
	)	class mail, in an envelope
Filed: October 23, 2003	)	addressed to:
	)	Mail Stop Amendment
For: METHOD AND COMPOSITION FOR	)	Commissioner for Patents
PREVENTING AND TREATING SOLID	)	P.O. Box 1450
TUMORS	)	Alexandria, VA 22313-1450
	)	
Attorney Docket No. 27611/38802A	)	Dated: April 7, 2005
	)	
Group Art Unit: 1642	)	
	)	
Examiner: Brandon J. Fetterolf,	)	
Ph.D.	)	James J. Napoli
	)	Registration No. 32,361
	)	Attorney for Applicants

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In response to the Office Action dated March 8, 2005, applicants hereby elect the invention represented by the claims of examiner's Group I, namely, claims 1-13, with traverse, for examination on the merits at this time. Applicants also elect, with traverse, the endothelin agonist identified as BQ123. Applicants further elect, with traverse, a breast tumor as the tumor, and paclitaxel as the chemotherapeutic agent. It is submitted, however, that all endothelin

agonists should be examined at this time. The novelty of the invention is use of an endothelin agonist in the treatment of a solid tumor. Individual endothelin agonists are not independent and distinct inventions because the statutory requirements of 35 U.S.C. §121, namely, independence and distinctness, are not present herein.

The individual endothelin agonists are not independent inventions because the endothelin agonists set forth in the claims are so closely related that a search for applicants' elected endothelin agonist would necessarily encompass a search for the remaining endothelin agonists.

In addition, even if individual endothelin agonists are considered independent inventions, there is no evidence that a search and examination directed to endothelin agonists in general would be a *serious burden* on the examiner, as is required by M.P.E.P. §803. ("If the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions." and "There must be a serious burden on the examiner if restriction is not required.")

In particular, it is submitted that a complete search directed to applicant's elected endothelin agonist would require a search directed to endothelin agonists in general, and vice versa.

Because search and examination of all endothelin agonists can be made without serious burden on the examiner, it would be wasteful of the time, effort,

and resources of both the applicants and the Patent Office to prosecute each endothelin agonist in separate applications. Search and examination of all endothelin agonists in a single application would be much more efficient than requiring the Patent Office to prosecute each endothelin agonist in separate applications. Search and examination of all endothelin agonists of claims in a single application would be much more efficient than requiring the Patent Office and applicants to do so in separate applications. Accordingly, it is submitted that all endothelin agonists should be examined at this time.

With respect to the election of a single tumor, the claims recite a solid tumor, and as such, these tumors are sufficiently related such that the search could be expanded, without a serious burden, to encompass solid tumors in general, as opposed to solely breast tumors.


Likewise, the election of a single chemotherapeutic agent is unduly restrictive. The treatment involves diagnosis of a solid tumor and treatment using a chemotherapeutic agent effective for treating the tumor. The administration of an endothelin agonist potentiates the chemotherapeutic effect, and this effect is independent of the chemotherapeutic agent. Accordingly, it is submitted that all chemotherapeutic agents should be examined at this time.

Reconsideration and withdrawal of the restriction requirement are respectfully requested. An early action on the merits is solicited.



Respectfully submitted,

**MARSHALL, GERSTEIN & BORUN LLP**

By   
James J. Napoli  
(Registration No. 32,361)  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606  
(312) 474-6300

Chicago, Illinois  
April 7, 2005